Staff Profile

Qualifications

1987  BSc Biochemistry (1^st class Hons), University of London

1990  MBBS (Hons), University of London

1993 MRCP (UK), London

2000 PhD, University of London

2010  FRCP, London

Previous positions

1999-2002  Wingate Lecturer, Nephrology and Transplantation, King’s College London

2002-2005  Wellcome Advanced Fellow, King's College London

2005-2007  Senior Lecturer, King’s College London 

Memberships and Responsibilities

Academic Vice President and Trustee, Renal Association

Chair, Kidney Research UK Scientific Committee

British Transplant Society

Association of Physicians of UK and Northern Ireland

UK Kidney Research Collaboration (UKKRC)

Areas of expertise

• Complement biology
• Kidney transplantation
• Atypical haemolytic uraemic syndrome
• Chronic kidney Disease
• Renal fibrosis
• C3 glomerulopathy

The complement system is an integral part of the immate immune system. In health it is responsinble for the elimination of pathogens and immune complexes. Excessive activation can lead to to tissue injury. I am interested in the role played by complememt in various types of kidney injury including, glomerular disease, interstitial inflammation and ischaemia reperfusion injury.

Fibrosis is the common pathway that leads to organ failure in many diverse diseases affecting different organs. In the kidney interstitial fibrsosis is characteristic of all progressive nephropathies that lead to renal failure. Becasue of the importance of fibrosis in clinical disease it is vital that we understand the mechanisms of renal fibrosis so that novel therapeutic targets can be identified and drugs developed. My group is studying the underlying pathological processes that lead to kidney fibrosis. This includes the role of chronic inflammation, including the complement system, the cell signalling pathways that initiate a fibrotic response and testing novel therapeutic interventions in pre-clinical model systems of fibrosis. Work is also underway to identify new non-invasive biomarkers that identifypatients with progressive renal fibrosis.

I lead the renal clinical research group at the Freeman. This is a team of research nurses, a study co-ordinator and data manager. We actively participate in a wide range of NIHR portfolio clinical trials in all aspects of Nephrology and Transplantation. The infrastructure and research staff support allows clinical staff to develop their own clinical studies and for clinicians to be part of important national studies. My own clinical resarch integrates with basic science, but also includes studying the severity and cause of the symptoms experienced by patients with kidney disease.

I am the Senior Tutor for Intercalation with responsibility for medical students during their intercalated year. 

I established and am the Degree Programme Director for the Post Graduate Certificate in Transplantation.

I also lead the teaching on Renal Week which provides nephrology teaching to year 4 students on the MBBS programme.

• Articles

  • Duineveld C, Glover EK, Bouwmeester RN, van de Kar NCAJ, Kavanagh D, Wetzels JFM, Sheerin NS. Kidney Transplantation in Patients with aHUS: A Comparison of Eculizumab Prophylaxis Versus Rescue Therapy. Transplantation 2025, 109(3), 511-518.
  • Bryant A, Lecouturier J, Orozco-Leal G, Brocklebank V, Carnell S, Chadwick T, Dunn S, Johnson S, Kavanagh D, Kennedy C, Malina M, Montgomery E, Muirhead C, Oluboyede Y, Vale L, Weetman C, Wong E, Sheerin NS. Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trial. The Lancet Regional Health - Europe 2025, epub ahead of print.
  • Gilbert RD, Al-Dakkak I, Boothe C, Cobb TE, Gale DP, Griffin S, Marks SD, Scully M, Shenoy M, Waters A, Sheerin NS. Demographics and baseline disease characteristics of UK patients within the Global aHUS Registry . BMC Nephrology 2025, 26, 434.
  • Tingle SJ, Connelly C, Glover EK, Stenberg B, Mcneill A, Kourounis G, Gibson BG, Mahendran B, Bates L, Cooper M, Pook R, Lee S, Brown ML, Figueiredo R, Marchbank KJ, Ali S, Sheerin N, Wilson CH, Thompson ER. Contrast-enhanced ultrasound to assess kidney quality during ex situ normothermic machine perfusion. Transplant International 2025. In Press.
  • Evans A, Mawson P, Thomas H, Keen K, Watson CJ, McAuley DF, MacGowan GA, Sheerin NS, Fisher A, Shaw J, Yates H, Fallow A, Kounali D, Banks J, Stevens M, Paul R, Hodge R, Lawson E, Harvey D, Dark J. SIGNET: protocol for a multicentre, single-blind prospective, group sequential, randomised controlled trial to evaluate the benefits of a single dose of simvastatin given to potential organ donors declared dead by neurological criteria on outcomes in organ recipients. BMJ Open 2024, 14(9), e086352.
  • Kavanagh D, Ardissino G, Brocklebank V, Bouwmeester R, Bagga A, terHeine R, Johnson S, Licht C, Ma A, Noris M, Praga M, Rondeau E, Sinha A, Smith RJH, Sheerin NS, Trimarchi H, Wetzels J, Vivarelli M, Van de Kar N, Greenbaum LA. Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum. Kidney International 2024, 106(6), 1038-1050.
  • Tingle SJ, Chung N, Malik A, Kourounis G, Thompson E, Glover EK, Mehew J, Phillip J, Gardiner D, Pettigrew GJ, Callaghan C, Sheerin NS, Wilson CH. Donor Time to Death and Kidney Transplant Outcomes in the Setting of a 3-Hour Minimum Wait Policy. JAMA Network Open 2024, 7(11), e2443353.
  • Wong K, Pitcher D, Braddon F, Downward L, Steenkamp R, Masoud S, Annear N, Barratt J, Bingham C, Coward RJ, Chrysochou T, Game D, Griffin S, Hall M, Johnson S, Kanigicherla D, Karet Frankl F, Kavanagh D, Kerecuk L, Maher ER, Moochhala S, Pinney J, Sayer JA, Simms R, Sinha S, Srivastava S, Tam FWK, Thomas K, Turner AN, Walsh SB, Waters A, Wilson P, Wong E, Sy KTL, Huang K, Ye J, Nitsch D, Saleem M, Bockenhauer D, Bramham K, Gale DP, Abat S, Adalat S, Agbonmwandolor J, Ahmad Z, Alejmi A, Almasarwah R, Asgari E, Ayers A, Baharani J, Balasubramaniam G, Kpodo FJ-B, Bansal T, Barratt A, Bates M, Bayne N, Bendle J, Benyon S, Bergmann C, Bhandari S, Boddana P, Bond S, Branson A, Brearey S, Brocklebank V, Budwal S, Byrne C, Cairns H, Camilleri B, Campbell G, Capell A, Carmody M, Carson M, Cathcart T, Catley C, Cesar K, Chan M, Chea H, Chess J, Cheung CK, Chick K-J, Chitalia N, Christian M, Clark K, Clayton C, Clissold R, Cockerill H, Coelho J, Colby E, Colclough V, Conway E, Cook HT, Cook W, Cooper T, Crosbie S, Cserep G, Date A, Davidson K, Davies A, Dhaun N, Dhaygude A, Diskin L, Dixit A, Doctolero EA, Dorey S, Downard L, Drayson M, Dreyer G, Dutt T, Etuk K, Evans D, Finch J, Flinter F, Fotheringham J, Francis L, Gallagher H, Garcia EL, Gavrila M, Gear S, Geddes C, Gilchrist M, Gittus M, Goggolidou P, Goldsmith C, Gooden P, Goodlife A, Goodwin P, Grammatikopoulos T, Gray B, Griffith M, Gumus S, Gupta S, Hamilton P, Harper L, Harris T, Haskell L, Hayward S, Hegde S, Hendry B, Hewins S, Hewitson N, Hillman K, Hiremath M, Howson A, Htet Z, Huish S, Hull R, Humphries A, Hunt DPJ, Hunter K, Hunter S, Ijeomah-Orji M, Inston N, Jayne D, Jenfa G, Jenkins A, Jones CA, Jones C, Jones A, Jones R, Kamesh L, Frankl FK, Karim M, Kaur A, Kearley K, Khwaja A, King G, King G, Kislowska E, Klata E, Kokocinska M, Lambie M, Lawless L, Ledson T, Lennon R, Levine AP, Maggie Lai LW, Lipkin G, Lovitt G, Lyons P, Mabillard H, Mackintosh K, Mahdi K, Maher E, Marchbank KJ, Mark PB, Masunda B, Mavani Z, Mayfair J, McAdoo S, Mckinnell J, Melhem N, Meyrick S, Morgan P, Morgan A, Muhammad F, Murray S, Novobritskaya K, Ong AC, Oni L, Osmaston K, Padmanabhan N, Parkes S, Patrick J, Pattison J, Paul R, Percival R, Perkins SJ, Persu A, Petchey WG, Pickering MC, Pinney J, Plumb L, Plummer Z, Popoola J, Post F, Power A, Pratt G, Pusey C, Rabara R, Rabuya M, Raju T, Javier C, Roberts IS, Roufosse C, Rumjon A, Salama A, Sandford RN, Sandu KS, Sarween N, Sebire N, Selvaskandan H, Shah S, Sharma A, Sharples EJ, Sheerin N, Shetty H, Shroff R, Sinha M, Smith K, Smith L, Stott I, Stroud K, Swift P, Szklarzewicz J, Tam F, Tan K, Taylor R, Tischkowitz M, Tse Y, Turnbull A, Tyerman K, Usher M, Venkat-Raman G, Walker A, Watt A, Webster P, Wechalekar A, Welsh GI, West N, Wheeler D, Wiles K, Willcocks L, Williams A, Williams E, Williams K, Wilson DH, Wilson PD, Winyard P, Wood G, Woodward E, Woodward L, Woolf A, Wright D. Description and Cross-Sectional Analyses of 25,880 Adults and Children in the UK National Registry of Rare Kidney Diseases Cohort. Kidney International Reports 2024, 9(7), 2067-2083.
  • Kourounis G, Elmahmudi AA, Thomson B, Nandi R, Tingle S, Glover E, Thompson E, Mahendran B, Connelly C, Gibson B, Bates L, Sheerin NS, Hunter J, Ugail H, Wilson C. Deep Learning for Automated Boundary Detection and Segmentation in Organ Donation Photography. Innovative Surgical Sciences 2024, epub ahead of print.
  • Blakey H, Sun R, Xie L, Russell R, Sarween N, Hodson J, Hargitai B, Marton T, Neil DAH, Wong E, Sheerin NS, Bramham K, Harris CL, Knox E, Drayson M, Lipkin G. Pre-eclampsia is associated with complement pathway activation in the maternal and fetal circulation, and placental tissue. Pregnancy Hypertension 2023, 32, 43-49.
  • Thompson S, Pang CY, Sepuru KM, Cambier S, Hellyer TP, Scott J, Simpson AJ, Proost P, Kirby JA, Rajarathnan K, Sheerin NS, Ali S. Nitration of Chemokine CXCL8 acts as a natural mechanism to limit acute inflammation. Cellular and Molecular Life Sciences 2023, 80, 35.
  • Wilkins GC, Gilmour J, Giannoudaki E, Kirby JA, Sheerin NS, Ali S. Dissecting the Therapeutic Mechanisms of Sphingosine-1-Phosphate Receptor Agonism during Ischaemia and Reperfusion. International Journal of Molecular Sciences 2023, 24(13), 11192.
  • Gibson B, Connelly C, Moldakhmetova S, Sheerin NS. Complement activation and kidney transplantation; a complex relationship. Immunobiology 2023, 228(4), 152396.
  • Brocklebank V, Walsh PR, Smith-Jackson K, Hallam TM, Marchbank KJ, Wilson V, Bigirumurame T, Dutt T, Montgomery EK, Malina M, Wong EKS, Johnson S, Sheerin NS, Kavanagh D. Atypical haemolytic uraemic syndrome in the era of terminal complement inhibition- An observational cohort study. Blood 2023, 142(16), 1371-1386.
  • Glover EK, Smith-Jackson K, Brocklebank V, Wilson V, Walsh PR, Montgomery EK, Wong EKS, Johnson S, Malina M, Kavanagh D, Sheerin NS, Ahmed A, Ashby D, Awan A, Baker R, Bhandari S, Bingham C, Bommayya G, Border D, Breen C, Brown H, Brown A, Carmichael P, Chowdhury P, Curran S, Donne R, Dudley C, Dutt T, Eardley K, Eblamo-Abad E, Gale D, Griffin S, Harty J, Hewins P, Holt R, Ingham V, Kilbride H, Kingdon E, Lewis R, Mansfield N, Marks SD, Mason P, Mead P, Morton M, Muniraju T, Nagaraja P, Padmanabhan N, Plant N, Raftery T, Rowe P, Salama A, Shenbagaraman P, Taylor A, Tomlinson K, Torpey N, Uniacke M, Walbaum D, Webb M, Williams M, Woodman A, Shah S, Saif I. Assessing the Impact of Prophylactic Eculizumab on Renal Graft Survival in Atypical Hemolytic Uremic Syndrome. Transplantation 2023, 107(4), 994-1003.
  • Dunn S, Brocklebank V, Bryant A, Carnell S, Chadwick TJ, Johnson S, Kavannagh D, Lecouturier J, Malina M, Moloney E, Oluboyede Y, Weetman C, Wong EKS, Woodward L, Sheerin NS. Saftey and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open-label, prospective, single-arm study. BMJ Open 2022, 12(9), e054536.
  • Bottomley MJ, Beckwith H, McMahon A, Nation M, Wheeler DC, Greenwood S, Hughes J, Sheerin NS. Research engagement by British early-career practitioners in nephrology: A multidisciplinary survey. BMJ Open 2022, 12, e066212.
  • Thompson ER, Sewpaul A, Figuereido R, Bates L, Tingle SJ, Ferdinand JR, Situmorang GR, Ladak SS, Connelly CM, Hosgood SA, Nicholson ML, Clatworthy MR, Ali S, Wilson CH, Sheerin NS. MicroRNA antagonist therapy during normothermic machine perfusion of donor kidneys . American Journal of Transplantation 2022, 22(4), 1088-1100.
  • Tomazos I, Hatswell AJ, Cataland S, Chen P, Freemantle N, Lommele A, Deighton K, Knowles E, Sheerin NS, Rondeau E. Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: an indirect comparison using clinical trial data. Clinical Nephrology 2022, 97, 261-272.
  • Thompson ER, Bates L, Ibrahim IK, Sewpaul A, Stenberg B, McNeill A, Figueiredo R, Girdlestone T, Wilkins GC, Tingle SJ, Scott WE, Lamos H, Mellor AL, Roobrouck VD, Ting AE, Hosgood SA, Nicholson ML, Fisher AJ, Ali S, Sheerin NS, Wilson CH. Novel delivery of cellular therapy to reduce ischaemia reperfusion injury in kidney transplantation. American Journal of Transplantation 2021, 21(4), 1402-1414.
  • Flouri D, Lesnic D, Chrysochou C, Parikh J, Thelwall P, Sheerin N, Kalra PA, Buckley DL, Sourbron SP. Motion correction of free-breathing magnetic resonance renography using model-driven registration. Magnetic Resonance Materials in Physics, Biology and Medicine 2021, 34, 805-822.
  • Jordan NP, Tingle SJ, Shuttleworth VG, Cooke K, Redgrave RE, Singh E, Glover EK, Tajuddin HBA, Kirby JA, Arthur HM, Ward C, Sheerin NS, Ali S. MiR-126-3p Is Dynamically Regulated in Endothelial-to-Mesenchymal Transition during Fibrosis. International Journal of Molecular Sciences 2021, 22(16), 8629.
  • Wlodek E, Kirkpatrick RB, Andrews S, Noble R, Schroyer R, Scott J, Watson CJE, Clatworthy M, Harrison EM, Wigmore SJ, Stevenson K, Kingsmore D, Sheerin NS, Bestard O, Stirnadel-Farrant HA, Abberley L, Busz M, DeWall S, Birchler M, Krull D, Thorneloe KS, Weber A, Devey L. A pilot study evaluating GSK1070806 inhibition of interleukin-18 in renal transplant delayed graft function. PLoS ONE 2021, 16(3), e0247972.
  • Wang L, Wang T, Rushton SN, Parry G, Dark JH, Sheerin NS. The Impact of Severe Acute Kidney Injury Requiring Renal Replacement Therapy on Survival and Renal Function of Heart Transplant Recipients – A UK Cohort Study. Transplant International 2020, 33(12), 1650-1666.
  • Chadban SJ, Ahn C, Axelrod DA, Foster BJ, Kasiske BL, Kher V, Kumar D, Oberbauer R, Pascual J, Pilmore HL, Rodrigue JR, Segev DL, Sheerin NS, Tinckam KJ, Wong G, Balk EM, Gordon CE, Earley A, Rofeberg V, Knoll GA. Summary of the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation 2020, 104(4), 708-714.
  • Thompson P, Logan I, Tomson C, Sheerin N, Ellam T. Obesity, Sex, Race, and Early Onset Hypertension: Implications for a Refined Investigation Strategy. Hypertension 2020, 76(3), 859-865.
  • Brocklebank V, Kumar G, Howie AJ, Chandar J, Milford DV, Craze J, Evans J, Finlay E, Freundlich M, Gale DP, Inward C, Mraz M, Jones C, Wong W, Marks SD, Connolly J, Corner BM, Smith-Jackson K, Walsh PR, Marchbank KJ, Harris C, Wilson V, Wong EKS, Malina M, Johnson S, Sheerin NS, Kavanagh D. Long-term outcomes and response to treatment in DGKE nephropathy. Kidney International 2020, 97(6), 1260-1274.
  • Chadban SJ, Ahn C, Axelrod DA, Foster BJ, Kasiske BL, Kher V, Kumar D, Oberbauer R, Pascual J, Pilmore HL, Rodrigue JR, Segev DL, Sheerin NS, Tinckam KJ, Wong G, Knoll GA. KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation 2020, 104(4S1), S11-103.
  • Glover EK, Speight A, Televantou D, Needham S, Sheerin NS. Immunosuppression-induced clonal T-cell lymphoproliferative disease causing severe diarrhoea mimicking coeliac disease following renal transplantation: a case report. BMC Nephrology 2020, 21, 220.
  • Tingle SJ, Sewpaul A, Bates L, Thompson ER, Shuttleworth V, Figueiredo R, Ibrahim IK, Ali S, Wilson C, Sheerin NS. Dual microRNA blockade increases expression of antioxidant protective proteins; implications for ischaemia reperfusion injury. Transplantation 2020, 104(9), 1853-1861.
  • Leslie J, Garcia Macia M, Luli S, Worrell JC, Reilly W, Paish HL, Knox A, Barksby BS, Gee LM, Zaki MYW, Collins A, Burgoyne RA, Cameron R, Bragg C, Xu X, Chung GW, Brown CDA, Blanchard AD, Nanthakumar CB, Karsdal M, Robinson SM, Manas DM, Sen G, French J, White SA, Murphy S, Trost M, Zakrzewski JL, Klein U, Schwabe RF, Mederacke I, Nixon C, Bird T, Teuwen LA, Schoonjans L, Carmeliet P, Mann J, Fisher AJ, Sheerin NS, Borthwick LA, Mann DA, Oakley F. c-Rel orchestrates energy-dependant epithelial and macrophage reprogramming in fibrosis. Nature Metabolism 2020, 2, 1350-1367.
  • Altmann T, Torvell M, Owens S, Mitra D, Sheerin N, Morgan BP, Kavanagh D, Forsyth R. Complement Factor I deficiency: a potentially treatable cause of fulminant cerebral inflammation. Neurology: Neuroimmunology & Neuroinflammation 2020, 7(3), e689.
  • Menne J, Delmas Y, Fakhouri F, Licht C, Lommelé A, Minetti EE, Provôt F, Rondeau E, Sheerin NS, Wang J, Weekers LE, Greenbaum LA. Outcomes in Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab in a Long-term Observational Study. BMC Nephrology 2019, 20, 125.
  • Situmorang GR, Sheerin NS. Ischaemia reperfusion injury: mechanisms of progression to chronic graft dysfunction. Pediatric Nephrology 2019, 34(6), 951-963.
  • Ferreras L, Moles A, Situmorang G, el Masri R, Wilson I, Cooke K, Thompson E, Kusche-Gullberg M, Vivès M, Sheerin N, Ali S. Heparan sulfate in chronic kidney diseases: exploring the role of 3-O-sulfation. Biochimica et Biophysica Acta (BBA) - General Subjects 2019, 1863(5), 839-848.
  • Menne J, Delmas Y, Fakhouri F, Kincaid JF, Licht C, Minetti EE, Mix C, Provôt F, Rondeau E, Sheerin N, Wang J, Weekers LE, Greenbaum LA. Eculizumab Prevents Thrombotic Microangiopathy in Patients With Atypical Hemolytic Uremic Syndrome in a Long-Term Observational Study. Clinical Kidney Journal 2019, 12(2), 196-205.
  • Sevinc M, Stamp S, Ling J, Carter N, Talbot D, Sheerin NS. Comparison of the outcome of kidney transplantation after pulsatile or continuous ex vivo hypothermic machine perfusion of kidneys donated after cardiac death: analysis of kidney pairs. Transplantation Proceedings 2019, 51(6), 1785-1790.
  • Willows W, Odudu A, Logan I, Sheerin NS, Tomson C, Ellam T. Changing Protein Permeability with Nephron Loss; Evidence for a Human Remnant Nephron Effect. American Journal of Nephrology 2019, 50, 152-159.
  • Scott J, Finch T, Bevan M, Maniatopoulos G, Gibbins C, Yates B, Kilimangalam N, Sheerin NS, Kanagasundaram NS. Acute kidney injury electronic alerts: mixed methods Normalization Process Theory evaluation of their implementation into secondary care in England. BMJ Open 2019, 9(12), e032925.
  • Khalid U, Newbury LJ, Simpson K, Jenkins RH, Bowen T, Bates L, Sheerin NS, Chavez R, Fraser DJ. A urinary microRNA panel that is an early predictive biomarker of delayed graft function following kidney transplantation. Scientific Reports 2019, 9(1), 3584.
  • Martinez-Burgo B, Cobb S, Pohl E, Kashanin D, Paul T, Kirby JA, Sheerin N, Ali S. A C-terminal CXCL8 peptide based on chemokine-glycosaminoglycan interactions reduces neutrophil adhesion and migration during inflammation. Immunology 2019, 157(2), 173-184.
  • Shuttleworth VG, Gaughan L, Nawafa L, Mooney CA, Cobb SL, Sheerin NS, Logan IR. The methyltransferase SET9 regulates TGFB1 activation of renal fibroblasts via interaction with SMAD3. Journal of Cell Science 2018, 131, jcs207761.
  • Glover EK, Jordan N, Sheerin NS, Ali S. Regulation of Endothelial-to-Mesenchymal Transition by MicroRNAs in Chronic Allograft Dysfunction. Transplantation 2018, 103(4), e64-e73.
  • Hernandez-Fuentes MP, Franklin C, Rebollo-Mesa I, Mollon J, Delaney F, Perucha E, Stapleton C, Borrows R, Byrne C, Cavalleri G, Clarke B, Clatworthy M, Feehally J, Fuggle S, Gagliano S, Griffin S, Hammad A, Higgins R, Jardine A, Keogan M, Leach T, MacPhee I, Mark PB, Marsh J, Maxwell P, McKane W, McLean A, Newstead C, Augustine T, Phelan P, Powis S, Rowe P, Sheerin N, Solomon E, Stephens H, Thuraisingham R, Trembath R, Topham P, Vaughan R, Sacks SH, Conlon P, Opelz G, Soranzo N, Weale ME, Lord GM. Long- and short-term outcomes in renal allografts with deceased donors: A large recipient and donor genome-wide association study. American Journal of Transplantation 2018, 18(6), 1370-1379.
  • Fenton A, Montgomery E, Nightingale P, Peters AM, Sheerin N, Wroe AC, Lipkin GW. Glomerular filtration rate: new age- and gender- specific reference ranges and thresholds for living kidney donation. BMC Nephrology 2018, 19, 336.
  • Fearn A, Situmorang GR, Fox C, Oakley F, Howarth R, Wilson CL, Kiosia A, Robson MG, Mann DA, Moles A, Sheerin NS. The NF-kB1 is a key regulator of acute but not chronic renal injury. Cell Death and Disease 2017, 8, e2883.
  • Legendre CM, Campistol JM, Feldkamp T, Remuzzi G, Kincaid JF, Lommele A, Wang J, Weekers LE, Sheerin NS. Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis. Transplant International 2017, 30(12), 1275-1283.
  • Connor TM, Hoer S, Mallett A, Gale DP, Gomez-Duran A, Posse V, Antrobus R, Moreno P, Sciacovelli M, Frezza C, Duff J, Sheerin NS, Sayer JA, Ashcroft M, Wiesener MS, Hudson G, Gustafsson CM, Chinnery PF, Maxwell PH. Mutations in mitochondrial DNA causing tubulointerstitial kidney disease. PLoS Genetics 2017, 13(3), e1006620.
  • Brocklebank V, Johnson S, Sheerin TP, Marks SD, Gilbert RD, Tyerman K, Kinoshita M, Awan A, Kaur A, Webb N, Hegde S, Finlay E, Fitzpatrick M, Walsh P, Wong EKS, Booth C, Kerecuk L, Salama A, Almond M, Inward C, Goodship TH, Sheerin N, Marchbank KJ, Kavanagh D. Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland. Kidney International 2017, 92(5), Pages 1261-1271.
  • Barker CE, Thompson S, O'Boyle G, Lortat-Jacob H, Sheerin NS, Ali S, Kirby JA. CCL2 nitration is a negative regulator of chemokine-mediated inflammation. Scientific Reports 2017, 7, 44384.
  • Cocchiaro P, Fox C, Tregidgo NW, Howarth R, Wood KM, Situmorang GR, Pavone LM, Sheerin NS, Moles A. Lysosomal protease cathepsin D; a new driver of apoptosis during acute kidney injury. Scientific Reports 2016, 6, 27112.
  • Fox C, Cocchiaro P, Oakley F, Howarth R, Callaghan K, Leslie J, Luli S, Wood KM, Genovese F, Sheerin NS, Moles A. Inhibition of lysosomal protease cathepsin D reduces renal fibrosis in murine chronic kidney disease. Scientific Reports 2016, 6, 20101.
  • Sevinc M, Stamp S, Ling J, Carter N, Talbot D, Sheerin N. Ex Vivo Perfusion Characteristics of Donation After Cardiac Death Kidneys Predict Long-Term Graft Survival. Transplantation Proceedings 2016, 48(10), 3251-3260.
  • Kanagasundaram NS, Bevan MT, Sims AJ, Heed A, Price DA, Sheerin NS. Computerised clinical decision support for the early recognition and management of acute kidney injury: a qualitative evaluation of end-user experience. Clinical Kidney Journal 2016, 9(1), 57-62.
  • Sheerin N, Kavanagh D, Goodship THG, Johnson S. A national specialised service in England for atypical haemolytic uraemic syndrome – the first year’s experience. QJM 2016, 109(1), 27-33.
  • Sheerin NS. Urinary tract infection. Medicine 2015, 43(8), 435-439.
  • Wilson CL, Murphy LB, Leslie J, Kendrick S, French J, Fox CR, Sheerin NS, Fisher A, Robinson JH, Tiniakos DG, Gray DA, Oakley F, Mann DA. Ubiquitin C-terminal hydrolase 1: A novel functional marker for liver myofibroblasts and a therapeutic target in chronic liver disease. Journal of Hepatology 2015, 63(6), 1421-1428.
  • Iqbal Z, Wood K, Carter V, Goodship TH, Brown AL, Sheerin NS. Thrombotic microangiopathy as a cause of chronic kidney transplant dysfunction: a case report demonstrating successful treatment with Eculizumab. Transplantation Proceedings 2015, 47(7), 2258–2261.
  • Ermini L, Weale ME, Brown KM, Howell WM, Vaughan R, Rebollo Mesa I, Chowdhury P, Sacks SH, Sheerin NS. Systematic assessment of the influence of complement gene polymorphisms on kidney transplant outcome. Immunobiology 2015, 221(4), 528-534.
  • Wong E, Challis R, Sheerin N, Johnson S, Kavanagh D, Goodship TH. Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS). Immunobiology 2015.
  • Hill FJ, McCloskey SJ, Sheerin N. From a fish tank injury to hospital haemodialysis: the serious consequences of drug interactions. BMJ Case Reports 2015.
  • Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen D, Delmas Y, Douglas K, Furman R, Gaber O, Goodship T, Herthelius M, Hourmant M, Legendre C, Remuzzi G, Sheerin N, Trivelli A, Loirat C. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney International 2015, 87, 1061-1073.
  • Khurram MA, Stamp S, Sheerin NS, Rix D, Cunningham AC, Carter N, Talbot T. Behaviour of Transplanted Tumours and Role of Matching in Rejection. Transplant Immunology 2015, 32(2), 121-125.
  • Nichols E, Barbour TD, Pappworth IY, Wong EKS, Palmer J, Sheerin N, Pickering MC, Marchbank KJ. An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy. Kidney International 2015, 88(6), 1314-1322.
  • Brooks AM, Carter V, Liew A, Marshall H, Aldibbiat A, Sheerin NS, Manas DM, White SA, Shaw JA. De Novo Donor-Specific HLA Antibodies Are Associated With Rapid Loss of Graft Function Following Islet Transplantation in Type 1 Diabetes. American Journal of Transplantation 2015.
  • Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome. New England Journal of Medicine 2013, 368(23), 2169-2181.
  • Haynes R, Baigent C, Harden P, Landray M, Akyol M, Asderakis A, Baxter A, Bhandari S, Chowdhury P, Clancy M, Emberson J, Gibbs P, Hammad A, Herrington W, Jayne K, Jones G, Krishnan N, Lay M, Lewis D, Macdougall I, Nathan C, Neuberger J, Newstead C, Pararajasingam R, Puliatti C, Rigg K, Rowe P, Sharif A, Sheerin N, Sinha S, Watson C, Friend P, The 3C Study Collaborative Group. Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol. Transplant Research 2013, 2(1), 7.
  • Brown JH, Tellez J, Wilson V, Mackie IJ, Scully M, Tredger MM, Moore I, McDougall NI, Strain L, Marchbank KJ, Sheerin NS, O'Grady J, Harris CL, Goodship THJ. Postpartum aHUS Secondary to a Genetic Abnormality in Factor H Acquired Through Liver Transplantation. American Journal of Transplantation 2012, 12(6), 1632-1636.
  • Ermini L, Wilson IJ, Goodship THJ, Sheerin NS. Complement polymorphisms: Geographical distribution and relevance to disease. Immunobiology 2012, 217(2), 265-271.
  • Ermini L, Goodship THJ, Strain L, Weale ME, Sacks SH, Cordell HJ, Fremeaux-Bacchi V, Sheerin NS. Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS. Molecular Immunology 2012, 49(4), 640-648.
  • Murtagh FEM, Sheerin NS, Addington-Hall J, Higginson IJ. Trajectories of Illness in Stage 5 Chronic Kidney Disease: A Longitudinal Study of Patient Symptoms and Concerns in the Last Year of Life. Clinical Journal of the American Society of Nephrology 2011, 6(7), 1580-1590.
  • Murphy EL, Murtagh FEM, Carey I, Sheerin NS. Understanding Symptoms in Patients with Advanced Chronic Kidney Disease Managed without Dialysis: Use of a Short Patient-Completed Assessment Tool. Nephron Clinical Practice 2009, 111(1), C74-C80.
  • Li K, Zhou WD, Hong YZ, Sacks SH, Sheerin NS. Synergy between type 1 fimbriae expression and C3 opsonisation increases internalisation of E-coli by human tubular epithelial cells. BMC Microbiology 2009, 9(1), 64.
  • Murtagh FE, Murphy E, Sheerin NS. Illness trajectories: an important concept in the management of kidney failure. Nephrology, Dialysis, Transplantation 2009, 23(12), 3746-3748.
  • Newton J, Brown A, Sheerin NS. Fatigue in early renal disease. British Journal of Renal Disease 2009, 14(2).
  • Tang Z, Lu B, Hatch E, Sacks SH, Sheerin NS. C3a mediates epithelial-to-mesenchymal transition in proteinuric nephropathy. Journal of the American Society of Nephrology 2009, 20(3), 593-603.
  • Li K, Sacks SH, Sheerin NS. The classical complement pathway plays a critical role in the opsonisation of uropathogenic Escherichia coli. Molecular Immunology 2008, 45(4), 954-962.
  • Sheerin NS, Risley P, Abe K, Tang Z, Wong W, Lin T, Sacks SH. Synthesis of complement protein C3 in the kidney is an important mediator of local tissue injury. FASEB Journal 2008, 22(4), 1065-1072.
  • Tapmeier TT, Brown KL, Tang Z, Sacks SH, Sheerin NS, Wong W. Reimplantation of the ureter after unilateral ureteral obstruction provides a model that allows functional evaluation. Kidney International 2008, 73(7), 885-889.
  • Ting SM, Lee D, Maclean D, Sheerin NS. Paranoid Psychosis and Myoclonus: Flecainide Toxicity in Renal Failure. Cardiology 2008, 111(2), 83-86.
  • Murtagh FE, Marsh JE, Donohoe P, Ekbal NJ, Sheerin NS, Harris FE. Dialysis or not? A comparative survival study of patients over 75 years with chronic kidney disease stage 5. Nephrology Dialysis Transplantation 2007, 22(7), 1955-1962.
  • Chowdhury P, Sacks SH, Sheerin NS. Toll-like receptors TLR2 and TLR4 initiate the innate immune response of the renal tubular epithelium to bacterial products. Clinical and Experimental Immunology 2006, 145(2), 346-56.
  • Brown KM, Kondeatis E, Vaughan RW, Kon SP, Farmer CK, Taylor JD, He X, Johnston A, Horsfield C, Janssen BJ, Gros P, Zhou W, Sacks SH, Sheerin NS. Influence of Donor C3 Allotype on Late Renal-Transplantation Outcome. The New England Journal of Medicine 2006, 354(19), 2014-2023.
  • Lin T, Zhou W, Farrar CA, Hargreaves RE, Sheerin NS, Sacks SH. Deficiency of C4 from donor or recipient mouse fails to prevent renal allograft rejection. American Journal of Pathology 2006, 168(4), 1241-1248.
  • Li K, Feito MJ, Sacks SH, Sheerin NS. CD46 (Membrane Cofactor Protein) Acts as a Human Epithelial Cell Receptor for Internalization of Opsonized Uropathogenic Escherichia coli. Journal of Immunology 2006, 177(4), 2543-2551.
  • Sheerin NS, Abe K, Risley P, Sacks SH. Accumulation of Immune Complexes in Glomerular Disease Is Independent of Locally Synthesized C3. Journal of the American Society of Nephrology 2006, 17(3), 686-696.
  • Kucheria R, Dasgupta P, Sacks SH, Khan MS, Sheerin NS. Urinary tract infections: new insights into a common problem. Postgraduate Medical Journal 2005, 81(952), 83-86.
  • Keenan N, Jeyaratnam D, Sheerin NS. Mycobacterium simiae: a previously undescribed pathogen in peritoneal dialysis peritonitis. American Journal of Kidney Diseases 2005, 45(5), e75-78.
  • Kucheria R, Sheerin NS, Dasgupta P, Khan MS. Urinary tract infections: advances and new therapies. BJU International 2004, 93(6), 690-691.
  • Abe K, Li K, Sacks SH, Sheerin NS. The membrane attack complex, C5b-9, up regulates collagen gene expression in renal tubular epithelial cells. Clinical and Experimental Immunology 2004, 136(1), 60-66.
  • Chowdhury P, Sacks SH, Sheerin NS. Minireview: functions of the renal tract epithelium in coordinating the innate immune response to infection. Kidney international 2004, 66(4), 1334-1344.
  • Kouki P, Marsh JE, Sacks SH, Sheerin NS. Autoimmune renal injury in C3- and C4-deficient mice: a histological and functional study. Nephron Experimental Nephrology 2004, 96(1), e14-22.
  • Sheerin NS, Bhatacharia KF, Webb MC. Positron emission tomography in a patient with renal malacoplakia. American Journal of Kidney Diseases 2003, 42(3), E36-39.
  • Sheerin NS, Sacks SH. Leaked protein and interstitial damage in the kidney: is complement the missing link?. Clinical Experimental Immunology 2002, 130(1), 1-3.
  • Jayawardene SA, Sheerin N, Pattison JM, Hartley B, Goldsmith DJ. Spontaneous Abdominal Hemorrhage with AA-amyloidosis and Vasculitis in a Patient with Rheumatoid Arthritis. Journal of Clinical Rheumatology 2001, 7(2), 86-90.
  • Sheerin NS, Springall T, Abe K, Sacks SH. Protection and injury: the differing roles of complement in the development of glomerular injury. European Journal of Immunology 2001, 31(4), 1255-1260.
  • Masterson R, Sheerin N, Abbs I, Goldsmith D. Late allograft loss due to recurrence of p-ANCA-associated systemic vasculitis in a patient with relapsing polychondritis. Nephrology, Dialysis, Transplantation 2001, 16(8), 1705-1707.
  • Springall T, Sheerin NS, Abe K, Holers VM, Wan H, Sacks SH. Epithelial secretion of C3 promotes colonization of the upper urinary tract by Escherichia coli. Nature Medicine 2001, 7(7), 801-806.
  • Tahir H, Thomas G, Sheerin N, Bettington H, Pattison JM, Goldsmith DJ. Successful medical treatment of acute bilateral emphysematous pyelonephritis. American Journal of Kidney Diseases 2000, 36(6), 1267-1270.
  • N. S. Sheerin,S. H. Sacks. The local production of complement in the pathogenesis of renal inflammation. Nephrologie 1999, 20(7), 377-82.
  • Sheerin NS, Sacks SH, Fogazzi GB. In vitro erythrophagocytosis by renal tubular cells and tubular toxicity by haemoglobin and iron. Nephrol Dial Transplant 1999, 14(6), 1391-7.
  • N. S. Sheerin,P. Swift,J. Scoble. From malaria to transplantation: the evolution of treatment for the nephrotic syndrome in a single patient. Nephrol Dial Transplant 1999, 14(3), 800-1.
  • Tang S, Zhou W, Sheerin NS, Vaughan RW, Sacks SH. Contribution of renal secreted complement C3 to the circulating pool in humans. Journal of Immunology 1999, 162(7), 4336-4341.
  • Sheerin NS, Sacks SH. Chronic Interstitial Damage in Proteinuria. Does Complement Mediate Tubulointerstitial Injury?. Kidney Blood Pressure Research 1999, 22(1-2), 47-52.
  • Tang S, Sheerin NS, Zhou W, Brown Z, Sacks SH. Apical Proteins Stimulate Complement Synthesis by Cultured Human Proximal Tubular Epithelial Cells. Journal of the American Society of Nephrology 1999, 10(1), 69-76.
  • Sheerin NS, Springall T, Carroll M, Sacks SH. Altered distribution of intraglomerular immune complexes in C3-deficient mice. Immunology 1999, 97(3), 393-9.
  • N. S. Sheerin,S. H. Sacks. Complement and complement inhibitors: their role in autoimmune and inflammatory diseases. Curr Opin Nephrol Hypertens 1998, 7(3), 305-10.
  • D. Song,W. Zhou,S. H. Sheerin,S. H. Sacks. Compartmental localization of complement component transcripts in the normal human kidney. Nephron 1998, 78(1), 15-22.
  • N. S. Sheerin,W. Zhou,S. Adler,S. H. Sacks. TNF-alpha regulation of C3 gene expression and protein biosynthesis in rat glomerular endothelial cells. Kidney Int 1997, 51(3), 703-10.
  • N. S. Sheerin,T. Springall,M. C. Carroll,B. Hartley,S. H. Sacks. Protection against anti-glomerular basement membrane (GBM)-mediated nephritis in C3- and C4-deficient mice. Clin Exp Immunol 1997, 110(3), 403-9.
  • G. B. Fogazzi,N. S. Sheerin. IgA-associated renal diseases. Curr Opin Nephrol Hypertens 1996, 5(2), 134-40.
  • S. H. Sacks,W. Zhou,N. S. Sheerin. Complement synthesis in the injured kidney: does it have a role in immune complex glomerulonephritis?. J Am Soc Nephrol 1996, 7(11), 2314-9.
  • P. A. Andrews,N. S. Sheerin,J. A. Hicks,D. G. Williams,S. H. Sacks. Unusual presentations of anti-glomerular basement membrane antibody mediated disease are associated with delayed diagnosis and poor outcome. Clin Nephrol 1995, 44(4), 262-5.
  • N. Sheerin,N. K. Harrison,M. N. Sheppard,D. M. Hansell,M. Yacoub,T. J. Clark. Obliterative bronchiolitis caused by multiple tumourlets and microcarcinoids successfully treated by single lung transplantation. Thorax 1995, 50(2), 207-9.
  • N. Sheerin,J. F. Bourke,J. Holder,J. North,D. A. Burns. Bullous pemphigoid following radiotherapy. Clin Exp Dermatol 1995, 20(1), 80-2.
  • N. S. Sheerin,P. N. Monk,M. Aslam,H. Thurston. Simultaneous exposure to lead, arsenic and mercury from Indian ethnic remedies. Br J Clin Pract 1994, 48(6), 332-3.

• Book Chapter

  • Sheerin NS. Thrombotic microangiopathies. In: Harber M, ed. Practical Nephrology. London: Springer-Verlag London Ltd, 2014, pp.323-330.

• Conference Proceedings (inc. Abstracts)

  • Thelwall P, Parikh J, Pippard B, Wore C, Janiczek R, Sourbron S, Sheerin N. Detection of fibrosis in patients with moderate renal impairment with multiparametric MRI. In: International Society for Magnetic Resonance in Medicine Annual Meeting & Exhibition. 2021, Virtual.
  • Wang L, Wang T, Rushton SN, Parry G, Sheerin NS, Dark JH. The need for haemofiltration after lung transplantation is a marker of poor early outcomes, but has no deleterious long-term renal effect -- a UK cohort study. In: International Society for Heart and Lung Transplantation Annual Meeting. 2019, Orlando, Florida: Elsevier.
  • Wang L, Wang T, Rushton SN, Fisher AJ, Sheerin NS, Dark JH. Severe acute kidney injury after cardiac transplantation is a marker of poor early outcome and impacts on late renal function -- a UK cohort study. In: 39th International Society for Heart and Lung Transplantation Annual Meeting. 2019, Orlando, Florida: Elsevier.
  • Legendre C, Campistol J, Feldkamp T, Wang J, Remuzzi G, Weekers L, Sheerin N. Renal Outcome with Eculizumab in Patients with aHUS with Native and Transplanted Kidneys: Pooled Analysis of 100 Patients. In: 2016 American Transplant Congress. 2016, Boston, USA: Wiley-Blackwell Publishing, Inc.
  • Morton M, Chinnadurai R, Ahmed S, Sharma A, Dutt T, Bhutani S, Denley H, Augustine T, Goodship T, Sheerin N, Picton M. Management of Recurrent aHUS After Adult Kidney transplantation Despite Eculizumab Prophylaxis. In: 2016 American Transplant Congress. 2016, Boston, USA: Wiley-Blackwell Publishing, Inc.
  • Menne J, Delmas Y, Fakhouri F, Kincaid JF, Licht C, Minetti EE, Mix C, Provot F, Rondeau E, Sheerin N, Wang J, Weekers LE, Greenbaum LA. Long-Term follow-up study of Eculizumab for prevention of thrombotic microangiopathy in patients with atypical hemolytic uremic syndrome. In: 53rd ERA-EDTA Congress. 2016, Vienna, Austria: Oxford University Press.
  • Martinez Burgo M, Ali S, Kirby J, Sheerin N, Cobb S, Kashanin D. Ischemia-Reperfusion Injury Following Transplantation: Implications for the Modulation of CXCL8 Chemokine Function. In: 2016 American Transplant Congress. 2016, Boston, USA: Wiley-Blackwell Publishing, Inc.
  • Logan IR, Shuttleworth VG, Gaughan L, Nawafa LS, Sheerin NS. The Lysine Methyltransferase SETD7 is critical for TGF B-1 driven fibrosis. In: 52nd ERA-EDTA Congress. 2015, London, UK: Oxford University Press.
  • Fox C, Howarth R, Callaghan K, Wood KM, Oakley F, Sheerin N, Moles A. Pepstatin A improves renal fibrosis by impairing UPA lysosomal recycling. In: 52nd ERA-EDTA Congress. 2015, London, UK: Oxford University Press.
  • Afridi F, Coates R, Brown A, Arunachalam C, Baines L, Sheerin N, Talbot D. Outcomes of ABOi Renal Transplants: A single centre experience over a seven year period. In: 17th Congress of the European Society for Organ Transplantation (ESOT 2015). 2015, Brussels, Belgium: Wiley-Blackwell.
  • Nichols EM, Barbour TD, Kerr H, Pappworth IY, Wong EKS, Palmer J, Sheerin NS, Herbert A, Barlow PN, Pickering MC, Marchbank KJ. FH1-5^(18-20) ameliorates experimental C3 glomerulopathy; generation and testing of a murine version for further pre-clinical experiments. In: 15th European Meeting on Complement in Human Disease 2015. 2015, Uppsala, Sweden: Elsevier.
  • Sevinc M, Johnson J, Stamp S, Carter N, Ling J, Sheerin N, Talbot D. Ex Vivo perfusion characteristics of DCD kidneys predict long-term graft survival. In: 17th Congress of the European Society for Organ Transplantation. 2015, Brussels, Belgium: Wiley-Blackwell.
  • Sims A, Heed A, Bevan M, Sheerin NS, Price DA, Kanagasundaram NS. Electronic clinical decision support for the early recognition and management of acute kidney injury: quantitative evaluation of outcomes. In: 52nd Congress of the ERA-EDTA. 2015, London, UK: Oxford University Press.
  • Bevan M, Heed A, Sheerin NS, Sims A, Price DA, Kanagasundaram NS. Electronic Clinical Decision Support for the Early Recognition and Management of Acute Kidney Injury: Qualitative Evaluation of End-User Experience. In: 52nd Congress of the ERA-EDTA. 2015, London, UK: Oxford University Press.
  • Greenbaum LA, Delmas Y, Fakhouri F, Kincaid JF, Licht C, Minetti EE, Mix C, Provot F, Rondeau E, Sheerin N, Wang J, Weekers LE, Menne J. Eculizumab Prevents Thrombotic Microangiopathy: Long-Term Follow-up Study of Patients with Atypical Hemolytic Uremic Syndrome. In: 57th Annual Meeting and Exposition. 2015, Orlando, Florida: American Society of Hematology.
  • Parker S, Ali A, Sheerin N, Hall J, Pickard R. E. coli inhibits innate immunity to facilitate pyelonephritic infections. In: Annual Meeting of the Society-of-Academic-and-Research-Surgery. 2014, Univ Cambridge, Robinson Coll, Cambridge, ENGLAND: John Wiley & Sons, Ltd.
  • Legendre C, Cohen D, Delmas Y, Feldkamp T, Fouque D, Furman R, Gaber O, Greenbaum L, Goodship T, Haller H, Herthelius M, Hourmant M, Licht C, Moulin B, Sheerin N, Trivelli A, Bedrosian CL, Loirat C. Efficacy of Eculizumab in atypical hemolytic uremic syndrome (aHUS) patients with or without prior transplant. In: 50th ERA-EDTA Congress. 2013, Istanbul, Turkey: Oxford University Press.

• Editorials

  • Wong EKS, Brady M, Sheerin NS. Severe intestinal oedema due to nephrotic syndrome. QJM 2013, 106(2), 191-192.
  • Ali S, Sheerin NS. Biomarkers of acute injury: predicting the long-term outcome after transplantation. Kidney International 2013, 84(6), 1072-1074.
  • Logan IR, Sheerin NS. Anticoagulation and kidney injury: rare observation or common problem?. Journal of Nephrology 2013, 26(4), 603-605.
  • Sheerin NS. Should Complement Activation Be a Target for Therapy in Renal Transplantation?. Journal of the American Society of Nephrology 2008, 19(12), 2250-2251.

• Letters

  • Pearce H, Montgomery EK, Sheerin N, Ellam H. A Novel Case of CMV Resistance to Valganciclovir and Maribavir in a Renal Transplant Patient. Transplant International 2024, 37, 11985.
  • Frith J, Ng WF, Day CP, Payne B, Sheerin N, Gorman G, Jones D, Newton JL. Orthostatic intolerance is common in chronic disease - A clinical cohort study. International Journal of Cardiology 2014, 174(3), 861-862.
  • Wilson CH, Brown AL, White SA, Goodship THJ, Sheerin NS, Manas DM. Successful Treatment of De Novo Posttransplant Thrombotic Microangiopathy With Eculizumab. Transplantation 2011, 92(8), E42-E43.
  • Ingham V, Jayawardene S, O'Donnell P, Sheerin N. Diabetic glomerular disease: Pitfalls in diagnosis. NDT Plus 2009, 2(2), 187-188.
  • Murtagh FEM, Marsh JE, Donohoe P, Ekbal NJ, Harris FE, Sheerin NS. Dialysis or not? A comparative survival study of patients over 75 years of age with chronic kidney disease stage - Reply. Nephrology, Dialysis, Transplantation 2008, 23(5), 1769-1769.

• Reports

  • Wong E, Maville C, Allen G, Turnbull C, Naidoo L, Winn S, Oxley A, Walsh P, Brocklebank V, Montgomery E, Malina M, Johnson S, Sheerin N, Kavanagh D. The Annual Report of the National Renal Complement Therapeutics Centre 2022/23. Newcastle upon Tyne: 2024, 2024. The Annual Report of the National Renal Complement Therapeutics Centre.
  • Wong E, Maville C, Allen G, Turnbull C, Forster N, Naidoo L, Winn S, Montgomery M, Malina M, Johnson S, Sheerin N, Kavanagh D. The Annual Report of the National Renal Complement Therapeutics Centre 2021/22. Newcatle upon Tyne: National Renal Complement Therapeutics Centre, 2023. The Annual Report of the National Renal Complement Therapeutics Centre.
  • Wong E, Maville C, Allen G, Turnbull C, Forster N, Nicholl H, Winn S, Malina M, Johnson S, Sheerin N, Kavanagh D. The Annual Report of the National Renal Complement Therapeutics Centre 2020/21. Newcastle upon Tyne: National Renal Complement Therapeutics Centre, 2021. The Annual Report of the National Renal Complement Therapeutics Centre.
  • Wong E, Batchelor L, Maville C, Watt A, Forster N, Malina M, Johnson S, Sheerin N, Kavanagh D. The Annual Report of the National Renal Complement Therapeutics Centre 2019/20. Newcastle upon Tyne: National Renal Complement Therapeutics Centre, 2020. The Annual Report of the National Renal Complement Therapeutics Centre.
  • Wong E, Stout J, Ndebele J, Watt A, Batchelor L, Forster N, Malina M, Johnson S, Sheerin N, Kavanagh D. The Annual Report of the National Renal Complement Therapeutics Centre 2018/19. Newcastle upon Tyne: National Renal Complement Therapeutics Centre, 2019. The Annual Report of the National Renal Complement Therapeutics Centre.
  • Wong E, Stout J, Ndebele J, Watt A, Malina M, Johnson S, Sheerin N, Kavanagh D. The Annual Report of the National Renal Complement Therapeutics Centre 2017/18. Newcastle upon Tyne: National Renal Complement Therapeutics Centre, 2018. The Annual Report of the National Renal Complement Therapeutics Centre.
  • Wong E, Johnson S, Sheerin N, Kavanagh D. The Annual Report of the National Renal Complement Therapeutics Centre 2016/2017. Newcastle upon Tyne: National Renal Complement Therapeutics Centre, 2017. The Annual Report of the National Renal Complement Therapeutics Centre.

• Reviews

  • Thompson ER, Connelly C, Ali S, Sheerin N, Wilson C. Cell therapy during machine perfusion. Transplant International 2021, 34(1), 49-58.
  • Willows J, Brown M, Sheerin NS. The role of complement in kidney disease. Clinical Medicine 2020, 20(2), 156-160.
  • Glover EK, Sheerin NS. Urinary tract infection. Medicine 2019, 47(9), 546-550.
  • Oakley F, Gee LM, Sheerin NS, Borthwick LA. Implementation of pre-clinical methodologies to study fibrosis and test anti-fibrotic therapy. Current Opinion in Pharmacology 2019, 49, 95-101.
  • Glover E, Sheerin NS. Haemolytic uremic syndrome: diagnosis and management. F1000Research 2019, 8, 1690.
  • Thompson S, Martinez-Burgo B, Sepuru KM, Rajarathnam K, Kirby JA, Sheerin NS, Ali S. Regulation of chemokine function: The roles of GAG-binding and post-translational nitration. International Journal of Molecular Sciences 2017, 18(8), 1692.
  • Ferreras L, Sheerin NS, Kirby J, Ali S. Mechanisms of renal graft chronic injury and progression to interstitial fibrosis. Current Transplantation Reports 2015, 2, 259-268.
  • Fearn A, Sheerin NS. Complement activation in progressive renal disease. World Journal of Nephrology 2015, 4(1), 31-40.
  • Davison R, Sheerin NS. Prognosis and management of chronic kidney disease (CKD) at the end of life. Postgraduate Medical Journal 2014, 90(1060), 98-105.
  • Kavanagh D, Raman S, Sheerin NS. Management of hemolytic uremic syndrome. F1000 Prime Reports 2014, 6, 1-11.
  • Brown KM, Sacks SH, Sheerin NS. Mechanisms of disease: the complement system in renal injury - new ways of looking at an old foe. Nature Clinical Practice Nephrology 2007, 3(5), 277-286.